Cargando…
Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting
Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for patients with the 2019 coronavirus (COVID-19). However, little is known about their effectiveness in older adults and those at high risk of disease progression. This retrospective single-center observatio...
Autores principales: | Mutoh, Yoshikazu, Umemura, Takumi, Nishikawa, Takeshi, Kondo, Kaho, Nishina, Yuta, Soejima, Kazuaki, Noguchi, Yoichiro, Bando, Tomohiro, Ota, Sho, Shimahara, Tatsuki, Hirota, Shuko, Hagimoto, Satoshi, Takei, Reoto, Fukihara, Jun, Sasano, Hajime, Yamano, Yasuhiko, Yokoyama, Toshiki, Kataoka, Kensuke, Matsuda, Toshiaki, Kimura, Tomoki, Ichihara, Toshihiko, Kondoh, Yasuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054616/ https://www.ncbi.nlm.nih.gov/pubmed/36992519 http://dx.doi.org/10.3390/v15030811 |
Ejemplares similares
-
Effectiveness of monoclonal antibody therapy for COVID-19 patients using a risk scoring system
por: Mutoh, Yoshikazu, et al.
Publicado: (2022) -
Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022) -
New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19
por: Atmar, Robert L., et al.
Publicado: (2022) -
Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study
por: Mazzitelli, Maria, et al.
Publicado: (2023) -
Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2023)